<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) have previously been reported to show competitively high rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and proliferation in the bone marrow (BM) </plain></SENT>
<SENT sid="1" pm="."><plain>Using a double-labelling technique in the present study, we demonstrated that a significantly high number of S-phase cells were simultaneously apoptotic (signal antonymy; SA) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (mean +/- s.e.m </plain></SENT>
<SENT sid="2" pm="."><plain>53.5 +/- 6.7%, n = 24, P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, SA was negligible in <z:hpo ids='HP_0000001'>all</z:hpo> other specimens studied, including <z:mpath ids='MPATH_458'>normal</z:mpath> control BM (n = 13) from non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) patients, BM from patients with de novo <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (1'<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 5), or <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> that had transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (2'<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>; n = 10), or the <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> from patients with NHL (n = 9) or head and neck <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HNSCC</z:e>; n = 10) </plain></SENT>
<SENT sid="4" pm="."><plain>Subsequently, the expression of a transcription factor, E2F1, was studied in density-separated BM aspirate mononuclear cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (n = 9) and a <z:mpath ids='MPATH_458'>normal</z:mpath> control </plain></SENT>
<SENT sid="5" pm="."><plain>Two separate sets of primers were used that recognized the regulatory <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> (Rb) protein-binding region and the functional DNA-binding region of E2F1 </plain></SENT>
<SENT sid="6" pm="."><plain>Interestingly, although the latter manifested the expected band (280 bp) in <z:hpo ids='HP_0000001'>all</z:hpo> samples, the Rb-specific primers showed the expected band (380 bp) in the <z:mpath ids='MPATH_458'>normal</z:mpath> and in 4/9 MDS specimens </plain></SENT>
<SENT sid="7" pm="."><plain>Two other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> specimens also showed a smaller band ( approximately 325 bp), whereas 3/9 MDS patients showed exclusively the smaller band </plain></SENT>
<SENT sid="8" pm="."><plain>The levels of SA were significantly higher in those <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases that showed the smaller Rb-specific band either alone or in addition to the expected band (median 19.5%, n = 4, P = 0.037) than in those showing exclusively the expected band (median 0.4%, n = 3) </plain></SENT>
<SENT sid="9" pm="."><plain>Our present studies show SA as a characteristic feature of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and, importantly, demonstrate its link with an altered expression of E2F1 in some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>